Abstract # 2153 Bevacizumab in Patients Treated with Stereotactic Radiosurgery for Recurrent Malignant Gliomas is Associated with Improved Overall Survival

Presenter: Kyle Cuneo

About the Presenter:
Kyle Cuneo is third year resident in radiation oncology at Duke University Medical Center in Durham, NC. His research interests include the use of novel targeted agents with radiation therapy and stereotactic radiosurgery. Kyle went to medical school at Vanderbilt University and worked in the laboratory of Dennis Hallahan where his research focused on the effects of targeted agents and radiation on tumor vasculature. His current research mentor is John Kirkpatrick at Duke University Medical Center. Their ASTRO presentation examines the use of bevacizumab (anti-VEGF antibody) in patients treated with stereotactic radiosurgery for recurrent malignant gliomas. This retrospective analysis found that the use anti-VEGF therapy in this patient population was associated with improved overall survival. Kyle is working with Dr. Kirkpatrick on a prospective study to verify these results.
Contact the presenter at: kc91@notes.duke.edu


E-mail a friend about this poster:
Enter email address: